Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders

A. Carlo Altamura, R. Pioli, M. Vitto, R. Mannu

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The study aimed to evaluate the clinical response to venlafaxine in social phobia in 12 patients who were non-responders to selective serotonin reuptake inhibitors, and to assess how the response could be influenced by the comorbidity in Axis II with avoidant personality disorder (APD). The duration of the study was of 15 weeks using open flexible doses regimen in individuals with or without concomitant APD. The venlafaxine dose ranged from 112.5 mg/day to 187.5 mg/day. Venlafaxine improves social phobia and/or APD symptomatology, as demonstrated by decreasing Liebowitz Social Anxiety Scale total scores (P <0.05). In fact, venlafaxine significantly reduced the avoidant behaviour and specific sociophobic aspects, while notably improving the depression dimension and the basic anxiety symptoms. With regard to tolerability, the profile of venlafaxine was satisfactory with the main side-effects being nausea, headache and anxiety.

Original languageEnglish
Pages (from-to)239-245
Number of pages7
JournalInternational Clinical Psychopharmacology
Volume14
Issue number4
DOIs
Publication statusPublished - 1999

Fingerprint

Serotonin Uptake Inhibitors
Personality Disorders
Anxiety
Nausea
Headache
Comorbidity
Social Phobia
Venlafaxine Hydrochloride
Depression

Keywords

  • Avoidant personality disorder
  • Comorbidity
  • Depression
  • Hypersensitivity to criticism
  • Social phobia
  • SSRIs
  • Tolerability
  • Venlafaxine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Venlafaxine in social phobia : A study in selective serotonin reuptake inhibitor non-responders. / Altamura, A. Carlo; Pioli, R.; Vitto, M.; Mannu, R.

In: International Clinical Psychopharmacology, Vol. 14, No. 4, 1999, p. 239-245.

Research output: Contribution to journalArticle

@article{641995cc337441ceb81f20dc4b1d4993,
title = "Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders",
abstract = "The study aimed to evaluate the clinical response to venlafaxine in social phobia in 12 patients who were non-responders to selective serotonin reuptake inhibitors, and to assess how the response could be influenced by the comorbidity in Axis II with avoidant personality disorder (APD). The duration of the study was of 15 weeks using open flexible doses regimen in individuals with or without concomitant APD. The venlafaxine dose ranged from 112.5 mg/day to 187.5 mg/day. Venlafaxine improves social phobia and/or APD symptomatology, as demonstrated by decreasing Liebowitz Social Anxiety Scale total scores (P <0.05). In fact, venlafaxine significantly reduced the avoidant behaviour and specific sociophobic aspects, while notably improving the depression dimension and the basic anxiety symptoms. With regard to tolerability, the profile of venlafaxine was satisfactory with the main side-effects being nausea, headache and anxiety.",
keywords = "Avoidant personality disorder, Comorbidity, Depression, Hypersensitivity to criticism, Social phobia, SSRIs, Tolerability, Venlafaxine",
author = "Altamura, {A. Carlo} and R. Pioli and M. Vitto and R. Mannu",
year = "1999",
doi = "10.1097/00004850-199907000-00006",
language = "English",
volume = "14",
pages = "239--245",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Venlafaxine in social phobia

T2 - A study in selective serotonin reuptake inhibitor non-responders

AU - Altamura, A. Carlo

AU - Pioli, R.

AU - Vitto, M.

AU - Mannu, R.

PY - 1999

Y1 - 1999

N2 - The study aimed to evaluate the clinical response to venlafaxine in social phobia in 12 patients who were non-responders to selective serotonin reuptake inhibitors, and to assess how the response could be influenced by the comorbidity in Axis II with avoidant personality disorder (APD). The duration of the study was of 15 weeks using open flexible doses regimen in individuals with or without concomitant APD. The venlafaxine dose ranged from 112.5 mg/day to 187.5 mg/day. Venlafaxine improves social phobia and/or APD symptomatology, as demonstrated by decreasing Liebowitz Social Anxiety Scale total scores (P <0.05). In fact, venlafaxine significantly reduced the avoidant behaviour and specific sociophobic aspects, while notably improving the depression dimension and the basic anxiety symptoms. With regard to tolerability, the profile of venlafaxine was satisfactory with the main side-effects being nausea, headache and anxiety.

AB - The study aimed to evaluate the clinical response to venlafaxine in social phobia in 12 patients who were non-responders to selective serotonin reuptake inhibitors, and to assess how the response could be influenced by the comorbidity in Axis II with avoidant personality disorder (APD). The duration of the study was of 15 weeks using open flexible doses regimen in individuals with or without concomitant APD. The venlafaxine dose ranged from 112.5 mg/day to 187.5 mg/day. Venlafaxine improves social phobia and/or APD symptomatology, as demonstrated by decreasing Liebowitz Social Anxiety Scale total scores (P <0.05). In fact, venlafaxine significantly reduced the avoidant behaviour and specific sociophobic aspects, while notably improving the depression dimension and the basic anxiety symptoms. With regard to tolerability, the profile of venlafaxine was satisfactory with the main side-effects being nausea, headache and anxiety.

KW - Avoidant personality disorder

KW - Comorbidity

KW - Depression

KW - Hypersensitivity to criticism

KW - Social phobia

KW - SSRIs

KW - Tolerability

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=0032794768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032794768&partnerID=8YFLogxK

U2 - 10.1097/00004850-199907000-00006

DO - 10.1097/00004850-199907000-00006

M3 - Article

C2 - 10468317

AN - SCOPUS:0032794768

VL - 14

SP - 239

EP - 245

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 4

ER -